Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Conditions
Keywords
Pneumonia, Pneumococcal, Infections, Streptococcal Infections, Pneumonia
Brief summary
This is a Phase 2 clinical study to support the use of AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of 3 different formulations of AFX3772 compared with Prevnar 13 (PCV13) and Prevnar 20 (PCV). Part 1 is the dose escalation, lead-in portion of the study in which infants at each dose level will be randomized 3:1 in sequential cohorts of increasing doses of AFX3772 or PCV13. In Part 2, infants will be randomized to receive either one of two dose levels of AFX3772 or PCV20.
Interventions
BIOLOGICALAFX3772
AFX3772 administered intramuscularly.
BIOLOGICALPrevnar 13
PCV13 administered intramuscularly.
BIOLOGICALPrevnar 20
PCV 20 administered intramuscularly.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
42 Days to 90 Days
Healthy volunteers
Yes
Inclusion criteria
• Is a full-term infant approximately 2 months of age at time of obtaining the informed consent.
Exclusion criteria
* Had prior administration of any pneumococcal vaccine. * Has a known or suspected hypersensitivity to AFX3772, PCV13, PCV20 or any components of the formulations used. * Has a known or suspected immunodeficiency or other conditions associated with immunosuppression that may require immunosuppressive drugs. In addition, the participant's biological mother has known HIV infection or known to be hepatitis B surface antigen positive. * Has any clinically significant allergic condition or history prior to the first vaccination for primary immunization series. * Has a history of microbiologically proven invasive disease caused by S. pneumoniae. * Has received immunoglobulins. * Has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection. * Has received systemic corticosteroids for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with solicited injection site events | Day 1 through Day 7 post-vaccination | The assessed solicited injection site events are tenderness, redness/erythema and swelling. |
| Percentage of participants with solicited systemic events | Day 1 through Day 7 post-vaccination | The assessed solicited systemic events are irritability, fever, decrease of appetite, increased sleep, and decrease in sleep. |
| Percentage of participants with AEs | Day 1 through Day 30 | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. |
| Percentage of participants with serious adverse events (SAEs) | Day 1 through 6 months post dose three | An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires in patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. Medical or scientific judgment will be exercised by the investigator in deciding whether SAE reporting is appropriate in other situations such as significant medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with a pneumococcal serotype-specific Immunoglobulin G (IgG) concentration of greater than or equal to (>=) 0.35 μg/mL or corresponding threshold | 30 days post-dose two, 30 days post-dose three | Immunological responses were assessed in terms of percentage of participants with a pneumococcal serotype-specific IgG concentration \>= 0.35 μg/mL or corresponding threshold. |
| Geometric mean concentration for serotype-specific IgG | 30 days post-dose two, 30 days post-dose three | Immunological responses were assessed in terms of IgG GMCs and expressed as titers. |
Countries
Puerto Rico, United States
Outcome results
None listed